[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Ottolini et al., 2017 - Google Patents

Alpha-synuclein at the intracellular and the extracellular side: functional and dysfunctional implications

Ottolini et al., 2017

View PDF
Document ID
13485565393116731225
Author
Ottolini D
Calí T
Szabò I
Brini M
Publication year
Publication venue
Biological chemistry

External Links

Snippet

Abstract Alpha-synuclein (α-syn) is an abundant neuronal protein whose physiological function, even if still not completely understood, has been consistently related to synaptic function and vesicle trafficking. A group of disorders known as synucleinopathies, among …
Continue reading at www.research.unipd.it (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2828—Prion diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Similar Documents

Publication Publication Date Title
Ottolini et al. Alpha-synuclein at the intracellular and the extracellular side: functional and dysfunctional implications
Mor et al. The usual suspects, dopamine and alpha‐synuclein, conspire to cause neurodegeneration
Burré et al. Cell biology and pathophysiology of α-synuclein
Choi et al. Crucial role of protein oligomerization in the pathogenesis of Alzheimer's and Parkinson's diseases
Snead et al. Alpha-synuclein function and dysfunction on cellular membranes
Caballero et al. Interplay of pathogenic forms of human tau with different autophagic pathways
Ghiglieri et al. Alpha-synuclein: from early synaptic dysfunction to neurodegeneration
Terada et al. The effect of truncation on prion-like properties of α-synuclein
Florenzano et al. Extracellular truncated tau causes early presynaptic dysfunction associated with Alzheimer’s disease and other tauopathies
Stroo et al. Cellular regulation of amyloid formation in aging and disease
Villar‐Piqué et al. Structure, function and toxicity of alpha‐synuclein: the Bermuda triangle in synucleinopathies
Tofaris Initiation and progression of α-synuclein pathology in Parkinson’s disease
Volpicelli-Daley et al. Formation of α-synuclein Lewy neurite–like aggregates in axons impedes the transport of distinct endosomes
Longhena et al. The Contribution of α‐Synuclein Spreading to Parkinson’s Disease Synaptopathy
Tramutola et al. It is all about (U) biquitin: Role of altered ubiquitin‐proteasome system and UCHL1 in Alzheimer disease
Orenstein et al. Interplay of LRRK2 with chaperone-mediated autophagy
Gallegos et al. Features of alpha-synuclein that could explain the progression and irreversibility of Parkinson's disease
Alberio et al. Cellular models to investigate biochemical pathways in Parkinson’s disease
Kayed et al. Soluble endogenous oligomeric α-synuclein species in neurodegenerative diseases: Expression, spreading, and cross-talk
Surgucheva et al. γ-Synuclein: seeding of α-synuclein aggregation and transmission between cells
Ito et al. Molecular pathogenesis of seipin/BSCL2‐related motor neuron diseases
Hishikawa et al. Dorfin localizes to the ubiquitylated inclusions in Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, and amyotrophic lateral sclerosis
Bell et al. Modulation of the interactions between α-synuclein and lipid membranes by post-translational modifications
Cheng et al. Fatty acid-binding protein 7 triggers α-synuclein oligomerization in glial cells and oligodendrocytes associated with oxidative stress
Tong et al. Phospholipid transfer protein (PLTP) deficiency accelerates memory dysfunction through altering amyloid precursor protein (APP) processing in a mouse model of Alzheimer's disease